Information on mechanism of action, procedure, diagnostics, manufacturing, costs, risks and studies. Choose the pathway that best fits your situation.
You can first describe your situation in a structured way. A few details are enough for the first step; available medical reports can then be discussed selectively.
Learn how collaboration can be structured around diagnostics, organisational coordination, laboratory/manufacturing processes and logistics.
Who organises the process? Who carries medical responsibility? Where are dendritic cells manufactured – and why do we not publicly name our manufacturing partner? We answer these questions openly and without promises of cure.
IMMUMEDIC coordinates and provides information. The medically responsible healthcare professional decides on treatment. Manufacturing is carried out by a specialised manufacturing partner in Germany.
View transparency & responsibilities →No promise of cure and no automatic treatment recommendation – but a transparent first pathway through a complex situation.
Diagnosis, previous treatments and your current question.
Only if they are actually needed for the assessment.
DCT, diagnostics, evidence and possible topics for the next medical discussion.
Via the contact channel you prefer.
How do patients experience dendritic cell therapy and how does the disease develop during further follow-up?
Example: In a patient with metastatic breast cancer, the number of detected circulating tumour cells decreased in the documented course from 720 to 10 cells/ml.
The course occurred during combined treatment. A single case does not allow conclusions about treatment success in other patients.
Each page answers a specific patient or search question and links to further information.
Mechanism of action, antigen presentation and immunological context.
From medical review and blood collection to manufacturing and follow-up.
Patient-specific manufacturing, quality controls and organisational steps.
Cost components, diagnostics and questions about possible reimbursement.
What should be discussed with the treating physician before an individual decision.
Studies, limits of evidence and tumour-specific context.
No blanket claims of effectiveness: each tumour type requires its own assessment of standard therapy, tumour biology and the evidence base.
Standard treatment, immunological research, DCT context and studies.
Subtypes, established treatment and immunological context.
NSCLC/SCLC, biomarkers, immuno-oncology and DCT context.
Risk profile, systemic therapy and personalised immune approaches.
Standard therapy, tumour microenvironment and current evidence.
Molecular markers, standard therapy and immunotherapy context.
Assessment of important immune-cell populations in the clinical context.
Serial measurements can provide supplementary information; interpretation must always be combined with clinical findings and imaging.
Structured follow-up and temporal interpretation of measurement results.
The IMMUMEDIC press centre brings together current press releases, publications from 2025 and 2026 and selected international research on dendritic cell therapy.
A dedicated B2B section explains responsibilities, procedure, diagnostics, logistics and how to begin a possible collaboration.
Choose the appropriate entry point – patient or medical professional.
